Gene and cell doping (performance-enhancing)
Muscle & Strength · Gene/cell doping method
Tier F
High-risk evidence profile
Bottom line
Read Off Label grades Gene and cell doping (performance-enhancing) as F (1.7/10) based on preclinical evidence, unclear benefit magnitude, and a very high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 0/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
WADA coverage: nucleic acids, nucleic acid analogues, normal cells, genetically modified cells, cell components, nuclei, mitochondria and ribosomes when used for performance enhancement.
Studied, labeled, or reported-use context: Not a consumer dosing intervention — Experimental medical/research context only; WADA M3 prohibited method; not individualized guidance.
What the evidence says
WADA coverage: nucleic acids, nucleic acid analogues, normal cells, genetically modified cells, cell components, nuclei, mitochondria and ribosomes when used for performance enhancement. The 2026 list explicitly broadened cell-component language.
Mechanism
Gene-transfer, nucleic-acid, edited-cell and organelle-transfer strategies are pursued to alter muscle growth, oxygen delivery or repair pathways; the consumer version is mostly hypothetical and unsafe.
Studied, labeled, or reported dose & route
Not a consumer dosing intervention
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Gene and cell doping (performance-enhancing)'s effects?
- Read Off Label rates the evidence for Gene and cell doping (performance-enhancing) as Preclinical and the benefit magnitude as unclear, producing an overall grade of F (1.7/10). WADA coverage: nucleic acids, nucleic acid analogues, normal cells, genetically modified cells, cell components, nuclei, mitochondria and ribosomes when used for performance enhancement.
- What safety findings are reported for Gene and cell doping (performance-enhancing)?
- Gene and cell doping (performance-enhancing) has a very high risk profile in the database. Very High (oncogenesis, immune reactions, irreversible gene-expression effects, infection/procedural risk) Legal status: Experimental medical/research context only; WADA M3 prohibited method.
- What does the low Safety score for Gene and cell doping (performance-enhancing) represent?
- The Safety score is 0/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Gene and cell doping (performance-enhancing)?
- Not a consumer dosing intervention This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Gene and cell doping (performance-enhancing) work?
- Gene-transfer, nucleic-acid, edited-cell and organelle-transfer strategies are pursued to alter muscle growth, oxygen delivery or repair pathways; the consumer version is mostly hypothetical and unsafe.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.